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Abstract
Objective: Nicotinamide phosphoribosyltransferase (NAMPT), which is responsible for biosynthesis of nicotinamide 
adenine dinucleotide (NAD), has a regulatory role in cellular metabolism and thus, might be implicated in non-alcoholic 
fatty liver disease (NAFLD). This study aimed to show how NAMPT down-regulation in liver cells influences lipid 
metabolism and sirtiun 1 (SIRT1), as the main NAD-dependent deacetylase enzyme.
Materials and Methods: In this experimental study, HepG2 cells were transfected with NAMPT siRNA and hepatic 
triglyceride (TG) content and SIRT1 deacetylase activity were measured by colorimetric and fluorometric methods, 
respectively. Gene expression of fatty acid synthase (FAS) and sterol regulatory element-binding protein-1c (SREBP-
1c) was evaluated by real-time polymerase chain reaction (PCR). Total protein level and the phosphorylated form of 
acetyl-CoA carboxylase (ACC) and AMP-activated protein kinase (AMPK) were also investigated by western blotting. 
Results: Knockdown of NAMPT significantly promoted the accumulation of TG in HepG2 cells, accompanied by a 
remarkable decline in SIRT1 deacetylase activity. A significant rise in the gene expression of two key lipogenic factors, 
FAS and SREBP-1c was also observed. These effects were also accompanied by decreased phosphorylation of ACC 
and AMPK. On the other hand, treatment of transfected cells with either NAD, as the SIRT1 substrate or resveratrol, as 
the SIRT1 activator reversed the outcomes. 
Conclusion: These results demonstrated a protective role for NAMPT against NAFLD and its involvement in the 
regulation of de novo lipogenesis through the SIRT1/AMPK pathway. 
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Introduction
It is believed that non-alcoholic fatty liver disease 
(NAFLD) ranks among the most common liver disorders 
worldwide and shows increasing incidence within the 
past two decades (1). NAFLD ranges from simple fat 
deposition (steatosis) to non-alcoholic steatohepatitis 
(NASH), characterized by steatosis and inflammation. 
NASH can lead to fibrosis, cirrhosis, and eventually 
hepatocellular carcinoma (HCC) (2). 
Liver has a central role in lipid metabolism, and synthesis, 
and import of free fatty acids, as well as storing and exporting 
lipids and lipoproteins. In NAFLD, lipid deposition is 
increased because of elevated hepatic lipogenesis and 
increased lipid uptake. At the same time, reduced lipid 
removal caused by decreased β-oxidation and diminished 
TG export, causes a positive lipid balance in the liver leading 
to the progression of NAFLD (3). Obesity and its metabolic 
consequences such as insulin resistance and type 2 diabetes 
mellitus, are the most prevalent risk factors for dyslipidemia 
and steatosis development (4). 
Approximately 26% of liver lipids are produced by de 
novo lipogenesis and this pathway is induced in individuals 
with NAFLD (5). In this pathway, acetyl-CoA carboxylase 
(ACC) and fatty acid synthase (FAS) are major enzymes 
that are controlled by important transcription factors like 
carbohydrate response element-binding protein (ChREBP), 
sterol regulatory element-binding protein-1c (SREBP-1c) 
and liver X receptor (LXR) (6).
Nicotinamide phosphoribosyltransferase (NAMPT), 
an enzyme with two intra- and extracellular forms, is a 
52 kDa protein expressed in approximately all tissues/
cells (7). Extracellular NAMPT (eNAMPT), generally 
called visfatin, is secreted by visceral adipose tissue 
and functions as an adipokine and activates various cellular 
signaling pathways (8, 9). Intracellular form of the protein 
(iNAMPT) has an enzymatic activity and functions as the key 
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enzyme in NAD biosynthesis. NAD is an essential coenzyme 
in many metabolic reactions and has multiple roles in 
cellular metabolism (10). NAMPT catalyzes the synthesis of 
nicotinamide mononucleotide (NMN) from nicotinamide and 
5-phosphoribosyl-pyrophosphate (PRPP) (11). Nicotinamide 
mononucleotide adenylyltransferase (NMNAT) turns NMN 
into NAD (12). Some enzymes use NAD as substrate for 
their catalytic reactions such as the sirtuin family of protein 
deacetylases (13); one of them is silent information regulator 
1 (SIRT1) and its inhibition has been shown to be implicated 
in hepatic steatosis (14). SIRT1 controls the function of AMP-
activated protein kinase (AMPK), which is a central enzyme 
in energy homeostasis and fatty acid metabolism (15, 16). 
ACC phosphorylation and activity are respectively increased 
and repressed by AMPK phosphorylation. The subsequent 
decline in the synthesis of malonyl-CoA causes up-regulation 
of fatty acid oxidation and suppression of fatty acid synthesis, 
which lead to decreased levels of hepatocyte lipids (17). 
Moreover, glucose-induced expression of FAS is impeded by 
AMPK activation that hampers fatty acid biosynthesis and 
leads to decreased TG levels (18).
SREBP-1c is one of the main transcription factors that 
induces the expressions of lipogenic genes such as FAS, ACC 
and glycerol-3-phosphate acyltransferase (GPAT), and can 
affect the production of fatty acids and TG. Thus, SREBP-
1c plays a critical role in NAFLD (19). It was found that 
AMPK can phosphorylate SREBP-1c at Ser 372, suppress 
its translocation into the nucleus, and therefore repress the 
expression of its target genes (20). Increased expression of 
SIRT1 was shown to be a causative factor in SREBP-1c gene 
expression decline in obese mice (21). 
Recent studies suggested that NAMPT is involved in 
lipid metabolism in the liver; however, its mechanism is 
still not clearly defined (19, 22). A recent study showed that 
inhibition of NAMPT by its chemical inhibitor, FK866, 
aggravated hepatic lipid accumulation and steatosis in 
vivo and in vitro (19). Additionally, it was reported that 
NAMPT is necessary for de novo lipid biosynthesis in 
prostate cancer (PCa) cells (22). NAMPT expression was 
also shown to be reduced in the serum and liver tissue of 
patients with NAFLD (23).
Given the regulatory role of SIRT1 and AMPK in fatty acid 
and lipid metabolism, NAMPT might be related to NAFLD 
by provision of NAD as the main SIRT1 substrate. 
Some studies showed that circulating levels of 
eNAMPT/visfatin are elevated in NAFLD (24, 25). 
Conversely, downregulation of iNAMPT was recently 
reported in hepatic tissue of patients with NAFLD (23). 
Taken together, these studies point to the involvement 
of NAMPT in the pathogenesis of NAFLD; however, 
the associated molecular and metabolic mechanisms are 
not fully elucidated. In the current study, we inspected 
the effect of NAMPT knockdown on lipid accumulation, 
lipogenic factors, and SIRT1 activity in HepG2 cells. 
Materials and Methods
This experimental study was approved by the Ethics 
Committee of Tehran University of Medical Sciences (IR.
TUMS.REC1394.2182). 
Cell culture and transfection 
Human hepatoma cells (HepG2) were obtained and 
authenticated from Iranian Biological Resource Center 
(Tehran, Iran). All cell culture reagents were bought from 
Gibco (UK). HepG2 cells were kept at 37˚C in Dulbecco 
Modified Eagle medium (DMEM) containing fetal bovine 
serum (10%) and 100 µg/ml penicillin and streptomycin, 
in 5% CO2. Cells were transfected using polyethyleneimine 
(PEI, Thermo, USA) as transfection reagent. Approximately, 
5×105 cells were seeded in 2 ml of medium in 6-well plates 
for 24 hours, prior to transfection. Afterwards, the cells 
were incubated with serum-free medium for 6 hours and 
subsequently transfected with PEI alone (mock) or with either 
siRNA against NAMPT or its negative control (scrambled 
siRNA) from GenePharma (Shanghai, China). FAM-labeled 
control siRNA (GenePharma, Shanghai, China) was also used 
to monitor transfection efficiency. The siRNA was mixed 
with PEI at the nitrogen/phosphate (N/P) ratio of six (26). 
Cells were incubated with the transfection complex for 24 
hours. Afterwards, the transfection medium was substituted 
with fresh growth medium and the incubation was continued 
for another 24 hours. Cells with no treatment were considered 
control. Knockdown of NAMPT was confirmed by real-
time polymerase chain reaction (PCR) and western blotting. 
Resveratrol was also used to investigate the involvement 
of SIRT1. For this purpose, two different concentrations of 
resveratrol (20 and 50 µM) were examined according to the 
cytotoxicity test done by MTT (27, 28); eventually, because 
of better cell viability, 20 µM concentration was chosen for 
the experiments. The transfected cells were treated with 
resveratrol (20 µM) or NAD (1 mM) separately in fresh 
medium for 24 hours. 
Detection of SIRT1 deacetylase activity
To investigate the relationship between NAMPT 
knockdown and changes in SIRT1 activity, the effect of 
NAMPT knockdown by siRNA on SIRT1 deacetylase 
activity was assessed after transfection for 48 hours using 
an SIRT1 Activity Assay Kit (Fluorometric, Abcam, 
Cambridge, UK) following the manufacturer’s protocol. 
Briefly, a mixture including fluoro-substrate peptides and 
NAD as SIRT1 substrates was mixed with cell extracts or 
recombinant SIRT1 as the positive control. 
Then, a microplate reader was used to measure 
fluorescence for 60 minutes with 1-2 minute intervals at 
excitation and emission wavelength of 350 and 460 nm, 
respectively. Fluorescence intensity relative to untreated 
control cells was used to express the enzyme activity.
Oil red O staining
About 5×105 HepG2 cells were seeded in 2 ml of medium in 
6-well plates for 24 hours and transfected as described above. 
After transfection, cells were washed 3 times with phosphate 
buffered saline (PBS, Sigma Aldrich, Germany) and fixed 
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with 4% formaldehyde for 1 hour. Oil Red-O staining 
solution (0.5% in isopropanol) was added and incubated 
for 15 minutes at room temperature. Finally, the cells were 
washed 3  times with PBS. The cells were photographed 
under light microscopy. Isopropanol was added to the stained 
lipid droplets and the absorbance was measured at 492 nm.
Intracellular triglyceride measurement
Cells were harvested 48 hours after transfection and the 
intracellular TG content was measured. Pellets of cells 
were homogenized in 1 ml of 5% NP-40 solution. Then, 
slow heating was applied to the mixture to 80-100˚C 
in a water bath for 5 minutes; afterward, the mixture 
was let to cool down to room temperature. Then, it was 
centrifuged for 2 minutes at top speed for eliminating 
the insoluble materials. Next, a commercial kit (Abcam, 
UK) was applied to determine TG content of the resulting 
solution. The concentration of total protein was quantified 
by bicinchoninic acid (BCA) method by applying Pierce 
protein assay kit (Thermo, USA), and TG levels were 
presented as µg of lipid/mg of protein.
Real-time polymerase chain reaction 
RNA extraction kit (GeneAll, South Korea) was used 
for total RNA isolation. Reverse transcription reaction was 
performed using kit for cDNA synthesis (Thermo Fisher 
Scientific, Waltham, USA). StepOnePlus real-time PCR 
System (Applied Biosystems, USA) was applied using SYBR 
Green PCR Master Mix (Ampliqon, Denmark) to amplify the 
resulting cDNA. Relative gene expression was analyzed by 
ΔΔCt method and β-actin was used as the normalizer (29). 
The primer sequences are presented in Table 1.
Table 1:  The sequences of the used primers 










After transfection for 48 hours, cells were lysed by 
radio-immunoprecipitation assay (RIPA) buffer containing 
phenylmethylsulfonyl fluoride (PMSF) as the protease 
inhibitor. The concentration of the extracted protein 
was assessed using the BCA method. Electrophoresis 
was performed on 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gel to separate equal amounts of total 
proteins; then, they were transferred into polyvinylidene 
difluoride (PVDF) membranes. Subsequently, blocking 
was carried out by incubation of membranes for 3 hours 
at room temperature in tris-buffered saline containing 
5% skim milk and 0.1% tween-20 (TBST). Afterward, 
the membranes were incubated overnight at 4˚C, with 
rabbit primary antibodies (Cell Signaling Technology, 
USA) against NAMPT, phospho-AMPK (Thr172), 
total-AMPK, phosho-ACC (Ser 79), total -ACC, and 
GAPDH as the loading control at the dilution of 1:1000. 
Horseradish peroxidase-conjugated anti-rabbit antibody 
(Cell Signaling Technology, Danvers, USA) at 1:5000 
dilution, was used as the secondary antibody. The protein 
bands were visualized by exposing them to X-ray film 
after reaction with enhanced chemiluminescence (ECL) 
detection reagent. Densitometric analysis of the resulting 
bands was performed by ImageJ software (v1.52, NIH). In 
order to perform the blotting with different antibodies, the 
membranes were stripped, re-probed and visualized after 
blocking and incubating with the primary and secondary 
antibodies. 
Statistical analyses
Data are shown as mean ± SD of at least three separate 
experiments. One-way analysis of variance (ANOVA) 
together with Dunnett’s multiple comparison post-hoc 
test was used to evaluate significant differences among 
groups. GraphPad Prism software (version 5.04., USA) 
was applied for statistical analysis. A P<0.05 was 
considered statistically significant. 
Results
Confirmation of transfection 
Transfection efficiency was evaluated by FAM-siRNA 
under a fluorescence microscope and the results were 
indicative of efficient transfection (Fig.1A). In addition, 
knockdown of NAMPT was confirmed by real-time PCR 
as well as western blotting. Transfection with siRNA 
significantly downregulated both the mRNA and protein 
levels of NAMPT (by about 58 and 55 %, respectively), 
compared to the control (P<0.001, Fig.1B, C). 
Knockdown of NAMPT reduces SIRT1 activity 
Since NAMPT provides the substrate for SIRT1 
activity, we first tested the hypothesis that knockdown of 
NAMPT modulates SIRT1 deacetylase activity. As shown 
in Figure 2, when cells were transfected with siRNA, 
SIRT1 deacetylation activity was significantly reduced 
compared to the untreated control cells. This inhibition 
was removed when excessive amounts of NAD were 
provided, confirming that the reduction of SIRT1 activity 
was due to the loss of NAD production by NAMPT. 
Resveratrol, which is a well-characterized activator of 
SIRT1, also significantly reversed the effect of NAMPT 
knockdown, further confirming that the reduced SIRT1 
activity was due to the down-regulation of NAMPT. 
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Fig.1: Transfection of HepG2 cells with NAMPT siRNA. A. Transfection efficiency was tested by FAM-siRNA under a fluorescence microscope (right panel) 
compared to the image under the optical microscope (left panel) (scale bar: 50 µm). B. Decreased expression of NAMPT mRNA measured by real-time 
PCR. C. Protein levels evaluated by western blotting compared to untreated control cells, after transfection with siRNA (Si), and D. A representative 
blotting image. Transfected cells were also treated with NAD (1 mM) and resveratrol (Res) (20 µM). A representative
blotting image is shown and the data represent the mean ± SD. NAMPT; Nicotinamide phosphoribosyltransferase, PCR; Polymerase chain reaction, NAD; 
Nicotinamide adenine dinucleotide, *; P<0.05, ***; P<0.001 versus the control, and NC; Negative control (scrambled siRNA). 
Fig.2: Reduced SIRT1 activity in HepG2 cells after transfection with NAMPT 
siRNA (Si). Resveratrol (Res) or NAD ameliorated this effect and increased SIRT1 
activity. The results are mean ± SD of at least 3 independent experiments. 
NAMPT; Nicotinamide phosphoribosyltransferase, NAD; Nicotinamide adenine 
dinucleotide, *; P<0.05, **; P<0.01, ***; P<0.001 versus the control, and NC; 
Negative control (scrambled siRNA).
NAMPT affects hepatic lipid accumulation via SIRT1
In order to determine whether NAMPT is involved 
in hepatic steatosis, Oil Red O staining was performed. 
The results indicated that lipid content of HepG2 cells 
was significantly increased after NAMPT knockdown 
(Fig.3A, B). In addition, intracellular TG levels were 
measured following knockdown of NAMPT in HepG2 
cells. As it is shown in Figure 3C, NAMPT knockdown 
caused a remarkable rise in the TG content of cells 
compared to the control cells. Elevation of TG levels by 
NAMPT knockdown was notably reversed by addition 
of NAD, confirming the effect of NAMPT inhibition on 
hepatic steatosis. Interestingly, treatment with resveratrol 
significantly reduced the TG accumulation that indicated 
the involvement of SIRT1 in the effect of NAMPT on 
lipid metabolism in HepG2 cells.
NAMPT and SIRT1 cooperate in the regulation of 
lipid metabolism in liver cells through modulation of 
FAS and SREBP-1c 
To determine the participation of NAMPT in the gene 
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were transfected with NAMPT siRNA and the effect of 
NAMPT silencing was evaluated on FAS and SREBP-1 
mRNA expression. We showed that suppression of NAMPT 
was followed by a significant enhancement of FAS and 
SREBP-1 expression at mRNA levels. In comparison to the 
untreated control cells, we achieved 28 and 30% elevation 
in SREBP-1 and FAS mRNA levels, respectively (Fig.4A, 
B). The negative control siRNA had no influence on the 
expression of these genes. On the other hand, treatment with 
resveratrol or NAD reversed these effects and significantly 
decreased the SREBP-1c and FAS mRNA levels compared to 
the cells transfected with NAMPT siRNA.
Fig.3: Knockdown of NAMPT with siRNA (Si) promoted TG accumulation in HepG2 cells. A. Microscopic images of the intracellular lipid content after Oil 
Red O staining (scale bar: 50 µm). B. Relative intracellular lipid content which was measured spectrophotometrically at 492 nm after solubilization of Oil 
Red O stain. C. Intracellular TG level determined by enzymatic method. The data represent the mean ± SD of at least three independent experiments. 
NAMPT; Nicotinamide phosphoribosyltransferase, TG; triglyceride, NAD; Nicotinamide adenine dinucleotide, *; P<0.05, **; P<0.01, ***; P<0.001 versus 
the untreated control, and NC; Negative control (scrambled siRNA). 
Fig.4: Knockdown of NAMPT with siRNA (Si) in HepG2 cells enhanced the expression of genes involved in lipogenesis. A. mRNA levels of SREBP-1, B. mRNA levels 
of FAS, after knockdown of NAMPT. The results are mean ± SD of at least three independent experiments. NAMPT; Nicotinamide phosphoribosyltransferase, NAD; 





 Down-regulation of NAMPT affects phosphorylation 
of ACC and AMPK via SIRT1 
To characterize whether NAMPT takes part in 
regulating lipid metabolism in the liver, we assessed the 
influence of NAMPT knockdown on AMPK and ACC 
as the regulatory enzymes in lipogenesis. As shown in 
Figure 5, down-regulation of NAMPT by siRNA caused 
a significant decline in the phosphorylation levels of 
AMPK at Thr172 and ACC at Ser 79, by 42 and 32%, 
respectively, compared to the control cells, while the 
total levels of both ACC and AMPK protein were not 
changed. Conversely, treatment of the transfected cells 
with resveratrol or NAD significantly reversed the effect 
of NAMPT knockdown, suggesting the requirement of 
NAD for AMPK phosphorylation and the involvement of 
SIRT1 in the activation of AMPK and inhibition of ACC.
Fig.5: Evaluation of the effect of NAMPT knockdown with siRNA 
(Si) on AMPK and ACC phosphorylation in HepG2 cells by Western 
blotting followed by densitometric analysis of the resulting bands. A. A 
representative blotting image for pAMPK and total-AMPK. B. quantitative 
analysis of the ratio of pAMPKα to total-AMPKα. C. A representative 
blotting image for pACC and total-ACC. D. Quantitative analysis of the ratio 
of pACC to total-ACC. The levels of protein were normalized to GAPDH. 
The data are presented as mean ± SD of at least 3 separate experiments. 
*; P<0.05, **; P<0.01, ***; P<0.001 versus the untreated control, and NC; 
Negative control (scrambled siRNA). 
Discussion
NAFLD which is considered to be among the most 
prevalent liver disorders, is defined by the extent of lipid 
accumulation  in liver (30). It is believed that dysregulation 
of lipid synthesis ranks among the major reasons causing 
abnormal lipid accumulation in the liver (31).
Recent studies established the involvement of NAMPT 
in the regulation of lipid metabolism (22, 32). In this 
research, we examined the effect of NAMPT knockdown 
by siRNA on TG accumulation, SIRT1 activity, and 
lipogenic factors in HepG2 liver cells. The current study 
presents the first direct evidence that NAMPT influences 
lipid metabolism in HepG2 cells and modulates TG 
accumulation through SIRT1/AMPK pathway. 
One of the main findings of this study was that NAMPT 
knockdown resulted in lipid accumulation in HepG2 cells. 
Consistently, Wang et al. (19) and Zhou et al. (33) showed 
that inhibition of NAMPT aggravated hepatic lipid 
accumulation and steatosis. Additionally, it was reported 
that NAMPT is necessary for de novo lipid biosynthesis 
in cancer (22). These results together with our findings 
indicate that down-regulation of NAMPT might be an 
essential element contributing to the pathogenesis of 
NAFLD. The decreased expression of NAMPT in the 
hepatic tissue of animals kept on high fat diet as well as 
its decline in HepG2 cells treated with oleic acid is also 
suggestive of the role of NAMPT in controlling hepatic 
lipid metabolism (19, 33). NAMPT was also shown to 
be reduced in the liver tissue of patients with NAFLD, 
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and hepatic steatosis (23). NAMPT positively regulates 
SIRT1 activity through the enzymatic synthesis of NAD 
(19). Furthermore, SIRT1 was shown to be protective 
against hepatic steatosis (15). The levels of SIRT1 are 
generally reduced in patients with NAFLD (34). On 
the other hand, overexpression of SIRT1 prevents high 
glucose-induced lipid pile-up in HepG2 cells (15). Here 
we showed that NAMPT knockdown decreased NAD-
dependent deacetylase activity of SIRT1, leading to 
increased TG accumulation in HepG2. Supplementation 
of cells with NAD compensated the deleterious effect of 
NAMPT inhibition, pointing out the importance of NAD 
provision by NAMPT for the function of SIRT1. 
Consistent with our results, it was reported that 
by reestablishing SIRT1 activity and promoting the 
mitochondrial effectiveness through NAD supplementation, 
the fatty liver is ameliorated in mice (35, 36). Furthermore, 
Zhou et al. (33) confirmed that the age-related NAD deficit 
intensified vulnerability to NAFLD and contributed to diet-
induced steatohepatitis.
We also showed that treatment of transfected cells with 
resveratrol, a well-known and potent SIRT1 activator (37), 
reversed TG accumulation, confirming the involvement of 
SIRT1 in the effect of NAMPT on liver cells. Consistently, 
it was reported that treatment of 3T3-L1 adipocytes with 
resveratrol decreases TG accumulation and increases 
SIRT1 gene and protein expression (38). 
Another finding of the current study was that NAMPT 
influenced the phosphorylation of ACC and AMPK. The 
phosphorylation and subsequent stimulation of AMPK 
lead to inhibition of ACC through phosphorylation and 
shift the metabolic pathways from lipogenesis to lipid 
oxidation. Thus, increased TG accumulation following 
NAMPT down-regulation, can be attributed to reduced 
AMPK and increased ACC activities caused by the 
decline in SIRT1 function. 
The mRNA expression of FAS and SREBP-1, as major 
transcription factors in lipid metabolism, were also 
increased in HepG2 cells following NAMPT knockdown, 
an effect that was attenuated after treatment with NAD. 
Therefore, increased gene expression of SREBP-1 as well 
as FAS might serve as another mechanism linking NAMPT 
to hepatic steatosis. In agreement with our results, Wang 
et al. (19) showed  that NAMPT overexpression caused 
a dramatic decline in lipid content and decreased the 
expressions of genes that are responsible for the regulation 
of lipogenesis such as SREBP-1c, and its downstream 
targets including FAS and ACC.
We found that the effects of NAMPT on the above 
lipogenic factors were reversed by resveratrol. It was 
reported that SIRT1 is able to suppress the expression of 
FAS via activating AMPK (15). SIRT1 also downregulates 
hepatic SREBP-1c activity by deacetylation (21). Thus, it 
is suggested that the modulation of FAS and SREBP-1c 
by NAMPT may also occur through SIRT1. 
Altogether, these results suggest a protective role for 
NAMPT against NAFLD. Our findings are consistent 
with the previous observations that serum NAMPT had a 
significant negative correlation with the hepatic de novo 
lipogenesis and liver mitochondrial function (39, 40). 
Conclusion
These data demonstrate that down-regulation of 
NAMPT increases hepatic lipid accumulation through 
modulation of SIRT1/AMPK pathway, leading to 
increased expression of FAS and SREBP-1c as well as 
reduced phosphorylation of ACC. Thus, NAMPT might 
be considered to be central and upstream to pathogenesis 
of NAFLD and regarded as a therapeutic strategy for this 
disorder.
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